Table 1

Previous and ongoing clinical trials targeting tumor-associated glycans or lectins

TargetDrug candidateModalityPhaseCancer typeCitation/Trial ID
NeuGcGM3RacotumomabVaccineII/IIINSCLC(66 67),
NCT01460472
Lewis-Y antigenhu3S193mAbI/IIAdvanced epithelial cancer; platinum resistant/refractory ovarian, Fallopian tube and primary peritoneal carcinoma(70 71)
MUC1PankoMab-GEX (Gatipotuzumab)mAbI/IIAdvanced carcinoma; recurrent ovarian carcinoma(74 75)
Lewis-Y antigen SGN-15ADCIINSCLC(79)
Lewis-Y antigenBMS-1 82 248–1ADCIIMetastatic breast cancer(80)
CD22/CD19DT2219BsAbIRefractory B-cell malignancies(89)
TAG72CART72CAR TIAdvanced colorectal cancer(96)
Lewis-Y antigenLey-CAR TCAR TIAML(102)
Lewis-Y antigenLey-CAR TCAR TIAdvanced solid tumorsNCT03851146
GD2GD2-iCAR-PBTCAR TIMetastatic melanoma(105)
GD2GD2-CAR3 combined with lymphodepletion and PD-1 blockadeCAR TIRelapsed or refractory neuroblastoma(106)
IL15-GD2GINAKITCAR-NKTIPediatric neuroblastomaNCT03294954
STnTheratope ADCIIIMetastatic breast adenocarcinoma(115 116)
Siglec-15NC318mAbI/IIAdvanced or metastatic solid tumorsNCT03665285
  • ADC, antibody-drug conjugates; AML, acute myeloid leukemia; mAb, monoclonal antibody; MUC1, mucin 1; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1.